scholarly journals Effectiveness of high-flow nasal cannula during exercise training in subjects with chronic respiratory failure

2020 ◽  
Author(s):  
Yuichi Chihara ◽  
Tomomasa Tsuboi ◽  
Kensuke Sumi ◽  
Atsuo Sato

Abstract Backgrounds: There are no clinical data comparing the effect of exercise training using high fraction of inspired oxygen (FIO2) in combination with high flow through a high-flow nasal cannula (HFNC) with that of ordinary supplemental oxygen on exercise capacity in subjects with chronic respiratory failure (CRF) receiving long-term oxygen therapy (LTOT). The aim of this study was to compare the effect of 4 weeks of exercise training using high FIO2 in combination with high flow through an HFNC or supplemental oxygen via a nasal cannula on the 6-min walking distance of patients with CRF receiving LTOT.Methods: In this randomized study, 32 patients with CRF due to chronic obstructive pulmonary disease, interstitial pulmonary fibrosis, or bronchiectasis receiving LTOT were assigned to undergo 4 weeks of exercise training on a cycle ergometer using an HFNC (flow: 50 L/min) with a FIO2 of 1.0 (HFNC group; n=16) or ordinary supplemental oxygen via a nasal cannula (flow: 6 L/min) (oxygen group; n=16). Before and after 4 weeks of exercise training, a 6-min walking test, constant-load test, and blood sampling were performed.Results: Prior to exercise training, the endurance time of the constant-load exercise test using an HFNC was significantly longer than that reported with prescribed oxygen in daily LTOT (p=0.004) or a 6 L/min nasal cannula (p=0.0003). Following 4 weeks of exercise training, change in the 6-min walking distance was significantly greater in the HFNC versus the oxygen group (55.2±69.6 m vs. —0.5±87.3 m, respectively; p=0.04). The plasma levels of adrenaline, noradrenaline, and serum C-reactive protein were significantly decreased only in the HFNC group, after 4 weeks of exercise training.Conclusions: Despite heterogeneity in the effect among patients, exercise training using high FIO2 in combination with high flow through an HFNC is a potentially superior exercise training modality for CRF patients receiving LTOT.Clinical Trial Registration ― http://www.clinicaltrials.gov. Unique identifier: NCT02804243. Registered 13 June 2016.

2020 ◽  
Author(s):  
Yuichi Chihara ◽  
Tomomasa Tsuboi ◽  
Kensuke Sumi ◽  
Atsuo Sato

Abstract Backgrounds: There are no clinical data comparing the effect of exercise training using both high fraction of inspired oxygen (FIO2) and high flow through a high-flow nasal cannula (HFNC) with that of ordinary supplemental oxygen on exercise capacity in subjects with chronic respiratory failure (CRF) receiving long-term oxygen therapy (LTOT). Methods: In this randomized study, 32 patients with CRF receiving LTOT were assigned to undergo 4 weeks of exercise training on a cycle ergometer using an HFNC (flow: 50 L/min) with a FIO2 of 1.0 (HFNC group; n=16) or ordinary supplemental oxygen via a nasal cannula (flow: 6 L/min) (oxygen group; n=16). Before and after 4 weeks of exercise training, a 6-min walking test, constant-load test, and blood sampling were performed. Results: Prior to exercise training, the endurance time of the constant-load exercise test using an HFNC was significantly longer than that reported with prescribed oxygen in daily LTOT (p=0.004) or a 6 L/min nasal cannula (p=0.0003). Following 4 weeks of exercise training, change in the 6-min walking distance was significantly greater in the HFNC versus the oxygen group (55.2±69.6 m vs. —0.5±87.3 m, respectively; p=0.04). The plasma levels of adrenaline, noradrenaline, and serum C-reactive protein were significantly decreased only in the HFNC group, after 4 weeks of exercise training. Conclusions: Despite heterogeneity in the effect among patients, exercise training using both high FIO2 and high flow through an HFNC is a potentially superior exercise training modality for CRF patients receiving LTOT.Clinical Trial Registration ― http://www.clinicaltrials.gov. Unique identifier: NCT02804243. Registered 13 June 2016.


2020 ◽  
pp. respcare.07688
Author(s):  
Robert J Varipapa ◽  
Erik DiGiacomo ◽  
Daniel B Jamieson ◽  
Sameer Desale ◽  
Rajiv Sonti

2018 ◽  
Vol 18 (12) ◽  
pp. 1652-1653 ◽  
Author(s):  
Filippo Luca Fimognari ◽  
Massimo Rizzo ◽  
Olga Cuccurullo ◽  
Giovanna Cristiano ◽  
Roberto Ricchio ◽  
...  

2021 ◽  
pp. 088506662110575
Author(s):  
Molano Franco Daniel ◽  
Gómez Duque Mario ◽  
Beltrán Edgar ◽  
Villabon Mario ◽  
Hurtado Alejandra ◽  
...  

Introduction: The use of high-flow nasal cannulas (HFNC) in patients with hypoxemic ventilatory failure reduces the need for mechanical ventilation and does not increase mortality when intubation is promptly applied. The aim of the study is to describe the behavior of HFNC in patients who live at high altitudes, and the performance of predictors of success/failure of this strategy. Methods: Prospective multicenter cohort study, with patients aged over 18 years recruited for 12 months in 2020 to 21. All had a diagnosis of hypoxemic respiratory failure secondary to pneumonia, were admitted to intensive care units, and were receiving initial management with a high-flow nasal cannula. The variables assessed included need for intubation, mortality in ICU, and the validation of SaO2, respiratory rate (RR) and ROX index (IROX) as predictors of HFNC success / failure. Results: One hundred and six patients were recruited, with a mean age of 59 years and a success rate of 74.5%. Patients with treatment failure were more likely to be obese (BMI 27.2 vs 25.5; OR: 1.03; 95% CI: .95-1.1) and had higher severity scores at admission (APACHE II 12 vs 20; OR 1.15; 95% CI: 1.06-1.24). Respiratory rates after 12 (AUC .81 CI: .70-.92) and 18 h (AUC .85 CI: .72-0.90) of HFNC use were the best predictors of failure, performing better than those that included oxygenation. ICU mortality was higher in the failure group (6% vs 29%; OR 8.8; 95% CI:1.75-44.7). Conclusions: High-flow oxygen cannula therapy in patients with hypoxemic respiratory failure living at altitudes above 2600 m is associated with low rates of therapy failure and a reduced need for mechanical ventilation in the ICU. The geographical conditions and secondary physiological changes influence the performance of the traditionally validated predictors of therapy success. Respiratory rate <30 proved to be the best indicator of early success of the device at 12 h of use.


Sign in / Sign up

Export Citation Format

Share Document